Key result
Platelet inhibition is not influenced by levels of reticulated platelets during infusion of cangrelor (r = 0.06, p = 0.47), independent of the oral P2Y12-receptor inhibitor transitioning strategy.
Why the study?
Does the level of reticulated platelets influence the antiplatelet effect of cangrelor and transitioning strategies to oral P2Y12-receptor inhibitors in patients undergoing elective PCI?
RCT (n=110)
randomized
Does the level of reticulated platelets influence the antiplatelet effect of cangrelor and transitioning strategies to oral P2Y12-receptor inhibitors in patients undergoing elective PCI?
Effect estimate: r = 0.06
p-value: p=0.47
Platelet inhibition by cangrelor is not attenuated by higher levels of reticulated platelets, unlike thienopyridines, highlighting its consistent potency during PCI.
No takes yet. Share an insight, caveat, or question.
Cangrelor delivers consistent platelet inhibition during elective PCI irrespective of reticulated platelet levels; extends evidence of its reliability over thienopyridines.
Stratz et al. (2018) conducted an RCT in elective percutaneous coronary intervention (n=110). Oral P2Y12-receptor inhibitor transitioning strategies (prasugrel, ticagrelor, or clopidogrel) vs. Different transitioning strategies compared to each other was evaluated on Correlation of reticulated platelets and ADP-induced platelet reactivity during cangrelor infusion (r = 0.06, p=0.47). Platelet inhibition is not influenced by levels of reticulated platelets during infusion of cangrelor (r = 0.06, p = 0.47), independent of the oral P2Y12-receptor inhibitor transitioning strategy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: